Medical News Today: Immunotherapy could benefit patients with advanced non-small-cell lung cancer

Results from a pivotal phase 2/3 trial show more patients with advanced non-small-cell lung cancer could benefit from the FDA-approved immunotherapy drug pembrolizumab.